Veru to Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call on February 14

MIAMI, Feb. 07, 2018 -- Veru Inc. (NASDAQ:VERU) today announced that on February 14, 2018, the company will report financial results for its fiscal 2018 first quarter ended December 31, 2017, before the market opens.  Veru management will host a conference call that same day at 8 a.m. Eastern Time to review the company’s performance and answer questions.

Event Details
Interested investors may access the call by dialing 877-317-6789 from the U.S. or 412-317-6789 from outside the U.S. and asking to join the Veru Inc. call.

In addition, investors may access a replay of the conference call the same day beginning at approximately noon ET by dialing 877-344-7529 for US callers, or 412-317-0088 from outside the U.S., passcode 10116643.  The replay will be available for one week, after which, the recording will be available via the company’s website at https://verupharma.com/investors.

About Veru Inc.
Veru Inc. (Veru) is a biopharmaceutical company focused on urology and oncology.  Veru utilizes FDA's 505(b)(2) regulatory approval pathway to develop and commercialize drug candidates.  FDA's 505(b)(2) regulatory approval pathway is designed to allow for potentially expedited, lower cost and lower risk regulatory approval based on a previously established safety and efficacy profile of the product.  Veru is developing products under the 505(b)(1) pathway as well, which is the traditional new drug application (NDA) pathway. The company is currently developing drug product candidates: Tamsulosin DRS, slow release granules, and Tamsulosin XR capsules for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) (NDA planned 2018), Solifenacin DRG, slow release granules, for overactive bladder (urge incontinence, urgency and frequency of urination) (NDA planned 2019), Tadalafil/finasteride combination capsule for restricted urination because of an enlarged prostate (NDA planned 2019), VERU-944 (cis-clomiphene citrate) for hot flashes in men associated with prostate cancer hormone treatment (planned Phase 2 in 2018), VERU-722 (fixed ratio clomiphene citrate) for male infertility, and VERU-111 a novel oral anti-tubulin cancer therapy targeting alpha and beta tubulin for a variety of malignancies, including metastatic prostate, breast, endometrial and ovarian cancers (planned Phase1/2 in 2018).

To help support these clinical development programs, the company markets and sells the PREBOOST^® medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation which is being co-promoted with Timm Medical Technologies, Inc. and the FC2 Female Condom^® (now available by prescription in the US including through the virtual doctor smartphone app “HeyDoctor” at www.fc2.us.com) in the United States and through The Female Health Company Division in the Global Public Health Sector. The Female Health Company Division markets to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.  More information about Veru and its products can be found at www.verupharma.com, www.PREBOOST.com, www.fc2.us.com and www.fc2femalecondom.com. For corporate and investor-related information about the Company, please visit https://verupharma.com/investors.

Contact:
Kevin Gilbert     786-322-2213